| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma |
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment |
|
|
| Not yet recruiting | 4 | 75 | | | Auckland District Health Board, Auckland District Health Board | Hepatitis C | | | | |
2017-002008-28: A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program |
|
|
| Ongoing | 4 | 50 | Europe | Maviret 100 mg/40 mg tablets, Tablet, Maviret 100 mg/40 mg filmdragerade tabletter glekaprevir/pibrentasvir Maviret 100 mg/40 mg film-coated tablets | Region Skåne, Region Skane | Patients with chronic hepatitis C and without somatic and/or psychiatric contraindications to treatment will be offered participation in the study in a chronological inclusion procedure., Diseases [C] - Virus Diseases [C02] | | | | |
2017-005179-21: Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, uden betydende arvæv i leveren |
|
|
| Terminated | 4 | 227 | Europe | Maviret, Moderiba, Copegus, J05AX, J05AB04, Tablet, Maviret, Moderiba, Copegus | Department of infectious Diseases, Odense University Hospital, Danish regions | Chronic Hepatitis C Kronisk hepatitis C, Chronic Hepatitis C Kronisk leverbetændelse type C, Diseases [C] - Virus Diseases [C02] | | | | |
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
|
|
| Completed | 4 | 87 | US | Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI | University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC | Cardiovascular Diseases, Hepatitis C, Hiv | 12/22 | 12/22 | | |
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
|
|
| Recruiting | 4 | 30 | RoW | Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret | Kirby Institute | Hepatitis C | 02/26 | 02/26 | | |
QUICK-CURE, NCT04515797: QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
|
|
| Terminated | 4 | 2 | US | Glecaprevir and Pibrentasvir, Direct Acting Antiviral HCV Treatment, Mavyret | Massachusetts General Hospital | Kidney Failure, Hepatitis C, Kidney Disease, Chronic | 08/23 | 08/23 | | |
NCT04575896: Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
|
|
| Completed | 4 | 10 | US | Glecaprevir/pibrentasvir, Mavyret | Johns Hopkins University | End Stage Renal Disease, Hepatitis C | 11/23 | 12/23 | | |
NCT04508907: A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients |
|
|
| Active, not recruiting | 4 | 200 | US | Mavyret, Zetia | Mayo Clinic | Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection | 11/25 | 11/26 | | |
NCT05582681: HCV Test and Treat Utilizing Simplified HCV Patient Education |
|
|
| Terminated | 4 | 8 | US | Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir, G/P | Weill Medical College of Cornell University, AbbVie | Hepatitis C | 11/24 | 11/24 | | |
2017-002221-37: Six weeks of Glecaprevir/ pibrentasvir for patients with acute HCV infection. Sei settimane di terapia con Glecaprevir/ pibrentasvir per i pazienti con epatite acuta da HCV. |
|
|
| Terminated | 3/4 | 50 | Europe | Glecaprevir/Pibrentasvir, [Glecaprevir/Pibrentasvir], Film-coated tablet, MAVIRET n.AIC 045445018/E | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Abbvie | Acute HCV infection Epatite acuta da HCV, Acute HCV infection Epatite acuta da HCV, Diseases [C] - Virus Diseases [C02] | | | | |
2017-000694-37: A study to evaluate how effective and safe a simplified treatment monitoring strategy is when applied to people with chronic hepatitis C virus infection without liver disease and taking glecaprevir/pibrentasvir for 8 weeks |
|
|
| Completed | 3 | 375 | Europe | glecaprevir/pibrentasvir, ABT-493/ABT-530, Film-coated tablet | University of New South Wales Sydney, Abbvie Pty Ltd, University of New South Wales Sydney | Chronic hepatitis C virus infection, Chronic hepatitis C infection is infection with hepatitis C virus for more than 6 months, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04017338: Transplantation Using Hepatitis C Positive Donors, A Safety Trial |
|
|
| Recruiting | 3 | 40 | Canada | Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Maviret, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion, Normothermic EVLP | Jordan Feld, University Health Network, Toronto | Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection, Kidney Pancreas Infection, Hepatitis C | 12/20 | 12/24 | | |
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
NCT05446857: Glecaprevir/Pibrentasvir for the Treatment of PTSD |
|
|
| Completed | 2/3 | 10 | US | Glecaprevir / Pibrentasvir Pill, Mavyret | White River Junction Veterans Affairs Medical Center | PTSD | 04/24 | 04/24 | | |
NCT05637879: Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
|
|
| Recruiting | 2/3 | 92 | US | Glecaprevir/pibrentasvir, Mavyret, Placebo | White River Junction Veterans Affairs Medical Center | PTSD | 12/25 | 09/26 | | |
| Completed | 2 | 408 | Europe | Viekirax, Exviera (Dasabuvir), Harvoni, Ribavirin (film-coated 200mg), Ribavirin (hard capsule, 200mg), Ribavirin (film-coated, 400mg), Maviret, Film-coated tablet, , Viekirax, Exviera (Dasabuvir), Harvoni, Maviret | Imperial College London, NIHR Efficacy and Mechanism Evaluation Programme | Hepatitis C Infection (HCV) (genotype 1a/1b/4), Hepatitis C infection, Diseases [C] - Virus Diseases [C02] | | | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
| Completed | 1/2 | 62 | US | Zepatier, Mavyret | University of Pennsylvania, Merck Sharp & Dohme LLC | End Stage Renal Disease | 03/22 | 12/22 | | |
NCT07040319: Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV |
|
|
| Recruiting | 1/2 | 30 | US | Glecaprevir/pibrentasvir, GLE/PIB | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), AbbVie | Hepatitis C | 10/27 | 10/27 | | |
NCT04682509: A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation |
|
|
| Completed | 1 | 20 | US | Glecaprevir/pibrentasvir, Mavyret | NYU Langone Health | ESRD | 05/23 | 02/24 | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
|
|
| Recruiting | N/A | 60 | RoW | Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet | Kirby Institute | Hepatitis C, Liver Inflammation, Liver Cirrhoses | 02/25 | 02/25 | | |
| Completed | N/A | 17 | US | Suboxone, Buprenorphine Naloxone, Truvada, Pre-Exposure Prophylaxis (PrEP), Mavyret, Hepatitis C treatment | Duke University, Center for AIDS Research (CFAR), National Institute of Allergy and Infectious Diseases (NIAID) | Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C | 03/23 | 03/23 | | |
Maviret PMS, NCT03740230: An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs |
|
|
| Completed | N/A | 3134 | RoW | | AbbVie | Hepatitis C | 07/23 | 07/23 | | |
NeoVie, NCT04366973: A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers |
|
|
| Completed | N/A | 95 | Europe | | AbbVie | Hepatitis C Virus (HCV) | 12/23 | 12/23 | | |
NCT06367465: Feasibility and Acceptability of HCV Treatment in Pregnancy |
|
|
| Recruiting | N/A | 50 | US | Glecaprevir-pibrentasvir | Washington University School of Medicine | Hepatitis C, Pregnancy Complications | 02/26 | 02/26 | | |
NCT04214028: A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus |
|
|
| Completed | N/A | 50 | Japan | | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
NCT07419347: Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data |
|
|
| Recruiting | N/A | 2000 | Canada | | AbbVie | Hepatitis C Virus (HCV) | 06/26 | 06/26 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |